April 12, 2021
FDA: Class I recall of Medtronic’s Valiant Navion Thoracic Stent Graft System
Editor's Note
The Food & Drug Administration (FDA), on April 9, identified the recall of Medtronic’s Valiant Navion Thoracic Stent Graft System as Class I, the most serious.
The recall was initiated because of the risk of stent fractures and endoleak concerns. The system is used to repair lesions of the descending thoracic aorta.
There have been 11 reported issues, including two injuries and one death. Distribution dates were November 12, 2018 to February 10, 2021.
Read More >>
Free Daily News
- Study: Weekend effect raises risk of surgical patient mortality, complications
- 4-day workweek boosts job satisfaction, work-life balance for nurse leaders
- Open-heart surgery performed on infant mid-delivery
- Infusion pumps deemed high-risk in FDA early alert
- Stem cell researchers tout potential for sickle cell disease cure
- Study: Stem cell therapy restores vision in LSCD patients
- AMSURG launches nationwide campaign to spotlight rising colon cancer rates, urges early screening
- AAAHC seeks stakeholder feedback on revised v44 standards to elevate patient-centered care
- Hospital’s anesthesia reforms slash carbon footprint, expenses
- Study: Shifting imaging to outpatient centers could save billions
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement